The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
| Status: | Recruiting |
|---|---|
| Conditions: | High Cholesterol |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/13/2018 |
| Start Date: | June 2010 |
| End Date: | May 2020 |
| Contact: | Lisa C. Hudgins, M.D. |
| Email: | lih2013@nyp.org |
| Phone: | 646-317-0805 |
This repository will establish for the first time a system to carefully assess and monitor
over time the general health and the amount of cholesterol in the arteries of U.S. children
and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare
disorder have very high blood levels of cholesterol from birth due to the inheritance of an
abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death
occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the
cholesterol level, but the best treatment and the best way to monitor the effect of the
treatment on the arteries are unknown. The collection of clinical data and blood for analysis
of known and yet-to-be discovered markers and predictors of arterial disease will yield new
information about the natural history of the disorder and response to treatment. The
repository will greatly aid the development of specific protocols that seek to learn more
about this disease and new therapies.
over time the general health and the amount of cholesterol in the arteries of U.S. children
and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare
disorder have very high blood levels of cholesterol from birth due to the inheritance of an
abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death
occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the
cholesterol level, but the best treatment and the best way to monitor the effect of the
treatment on the arteries are unknown. The collection of clinical data and blood for analysis
of known and yet-to-be discovered markers and predictors of arterial disease will yield new
information about the natural history of the disorder and response to treatment. The
repository will greatly aid the development of specific protocols that seek to learn more
about this disease and new therapies.
Detailed information of "standard of care" procedures will be compiled in a database. These
include medical history and physical exam, lipid profiles and other standard blood tests,
dietary evaluation and counseling, cardiology evaluation including EKG and
echocardiogram,ultrasound of carotids and femoral arteries, CT angiogram and, if indicated,
intracoronary angiography (ICA) with intravascular ultrasound (IVUS) and stress echo or
nuclear stress testing.
The recommendation for treatment will be individualized. Current options are a) FDA approved
cholesterol-lowering medications: statins, ezetimibe b) LDL-apheresis c) liver transplant d)
portacaval shunt e) investigational drugs. Treatment of vascular and/or valvular disease may
include aspirin, beta blockers, clopidogrel, angioplasty with metal stent, coronary artery
bypass surgery, aortic valve repair/replacement.
Research procedures will include medical photos of skin xanthomas, blood assays
(apolipoproteins A and B, LDL particle size, homocysteine, TNF, IL-6, insulin, glucose, ICAM,
VCAM, P and E selectin, and endothelial progenitor cells), and DNA analysis of the genes for
the LDL receptor and other lipid-related genes.
include medical history and physical exam, lipid profiles and other standard blood tests,
dietary evaluation and counseling, cardiology evaluation including EKG and
echocardiogram,ultrasound of carotids and femoral arteries, CT angiogram and, if indicated,
intracoronary angiography (ICA) with intravascular ultrasound (IVUS) and stress echo or
nuclear stress testing.
The recommendation for treatment will be individualized. Current options are a) FDA approved
cholesterol-lowering medications: statins, ezetimibe b) LDL-apheresis c) liver transplant d)
portacaval shunt e) investigational drugs. Treatment of vascular and/or valvular disease may
include aspirin, beta blockers, clopidogrel, angioplasty with metal stent, coronary artery
bypass surgery, aortic valve repair/replacement.
Research procedures will include medical photos of skin xanthomas, blood assays
(apolipoproteins A and B, LDL particle size, homocysteine, TNF, IL-6, insulin, glucose, ICAM,
VCAM, P and E selectin, and endothelial progenitor cells), and DNA analysis of the genes for
the LDL receptor and other lipid-related genes.
Inclusion criteria:
1. Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:
- Documented, untreated fasting LDL cholesterol level of > 500 mg/dL and triglycerides <
200 mg/dL on a cholesterol-lowering diet for at least 8 weeks with secondary causes
excluded, AND:
- DNA confirmation of a double mutation of the LDL receptor or apoB gene OR
- LDL > 160 mg/dL in both biological parents not associated with a disorder know to
elevate LDL OR
- Coronary artery disease in one or both parents or grandparents < 55 years for
males, < 65 for females OR
- Tendinous/cutaneous xanthomas < age 10 or coronary artery disease < age 20
Exclusion criteria:
1. Inability of patient, or, if less than 18, a parent, to sign informed consent.
We found this trial at
1
site
New York, New York 10065
Principal Investigator: Lisa Hudgins, M.D.
Phone: 646-317-0805
Click here to add this to my saved trials
